Trials / Not Yet Recruiting
Not Yet RecruitingNCT07019181
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma： Single-arm Clinical Phase II Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluating the rate of pathologic complete remission in patients with squamous esophageal cancer treated perioperatively with tislelizumab in combination with chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks |
| DRUG | albumin-bound paclitaxel | albumin-bound paclitaxel 260mg/m2，day 1 of every 3 weeks |
| DRUG | Nedaplatin | Nedaplatin 80mg/m2，day 1 of every 3 weeks |
Timeline
- Start date
- 2025-07-30
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2025-06-13
- Last updated
- 2025-06-13
Source: ClinicalTrials.gov record NCT07019181. Inclusion in this directory is not an endorsement.